Episurf Medical continues preparations for its US IDE study by appointing Dr Michael A Kelly as special study advisor

Episurf Medical (NASDAQ: EPIS B) is approaching the filing of its application to conduct an IDE study in the US. As an important step in the design and structuring of the study, the company appoints Dr Michael A Kelly as special study advisor. Dr Kelly will work with Episurf Medical and advise the company on a broad range of topics related to its IDE study and US launch.

Dr Michael A Kelly is the Chairman of the Department of Orthopaedic Surgery at The Hackensack University Medical Center in New Jersey and was previously President of the prestigious American Knee Society. He is the founding Professor and Chairman for Orthopedic Surgery at Hackensack Meridian School of Medicine at Seton Hall University. Dr Kelly’s practice is focused on all aspects of knee surgery and he is the author of numerous scientific articles within the field. He co-edited the textbook Surgery of the Knee 2nd Edition. Dr Kelly has lectured throughout the U.S. and internationally on topics related to sports medicine and knee reconstruction and he is a member of many professional organizations, including the American Orthopaedic Society of Sports Medicine and the American Orthopaedic Association. Previously, Dr Kelly served as the head team physician of the New Jersey Nets in the NBA (National Basketball Association). Dr Kelly is a graduate from Georgetown University School of Medicine.

”I am looking forward to working with Episurf Medical, as treatment of this patient group is a challenge for the orthopaedic industry” says Dr Michael A Kelly.

“The feedback from orthopaedic surgeons in the US has been highly encouraging, and we are proud to have Dr Kelly as an advisor to Episurf Medical in this very important strategic initiative” says Pål Ryfors, CEO of Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 23 May 2018.